On Friday, an appeals court upheld an earlier ruling that canceled patents for a blockbuster multiple sclerosis drug owned by Teva Pharmaceuticals.
The original ruling canceled patents for the drug, Copaxone, in January 2017 after a Delaware judge decided that they describe obvious concepts. The ruling is a victory for several manufacturers looking to get into the market for a generics version, including Mylan and Novartis AG.
As of last year, Copaxone was generating about $4 billion in annual sales for Teva.
Read the full Reuters report.
[javascriptSnippet]